Search research articles
Contact Us
Filters
Showing results (141-150 of 146) with videos related to
Page
of 15
Sort By:
You have reached the last page of results.
This site can display upto 146 results.
Pilot and Feasibility Studies
|
November 7, 2024
Magnetic resonance imaging-guided single-fraction preoperative radiotherapy for early-stage breast cancer (the RICE trial): feasibility study
Ayyaz Qadir, Nabita Singh, Jenna Dean, et al.
The Lancet. Oncology
|
May 17, 2026
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials
Shankar Siva, Muhammad Ali, Nicholas Hardcastle, et al.
European Urology
|
October 8, 2024
Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial
Robert Huddart, Shaista Hafeez, Clare Griffin, et al.
The Lancet. Oncology
|
February 29, 2024
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial
Shankar Siva, Mathias Bressel, Mark Sidhom, et al.
The Lancet. Oncology
|
May 17, 2026
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study
Shankar Siva, David Pryor, Jarad Martin, et al.
BMJ Open
|
August 4, 2023
[<sup>18</sup>F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial
Eng-Siew Koh, Hui K Gan, Clare Senko, et al.
Page
of 15
Search research articles
Search
Showing results (141-150 of 146) with videos related to
Sort By:
Page
of 15
You have reached the last page of results.
This site can display upto 146 results.
Pilot and Feasibility Studies
|
November 7, 2024
Magnetic resonance imaging-guided single-fraction preoperative radiotherapy for early-stage breast cancer (the RICE trial): feasibility study
Ayyaz Qadir, Nabita Singh, Jenna Dean, et al.
The Lancet. Oncology
|
May 17, 2026
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials
Shankar Siva, Muhammad Ali, Nicholas Hardcastle, et al.
European Urology
|
October 8, 2024
Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial
Robert Huddart, Shaista Hafeez, Clare Griffin, et al.
The Lancet. Oncology
|
February 29, 2024
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial
Shankar Siva, Mathias Bressel, Mark Sidhom, et al.
The Lancet. Oncology
|
May 17, 2026
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study
Shankar Siva, David Pryor, Jarad Martin, et al.
BMJ Open
|
August 4, 2023
[<sup>18</sup>F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial
Eng-Siew Koh, Hui K Gan, Clare Senko, et al.
Page
of 15